Title:
ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2017/126587
Kind Code:
A1
Abstract:
The present invention relates to: a monoclonal antibody which can bind to an extracellular domain of human CC chemokine receptor 1 (CCR1) and can inhibit the activation of CCR1 with human CC chemokine ligand 15 (CCL15), or an antibody fragment of the monoclonal antibody; a hybridoma which can produce the antibody; a nucleic acid which has a nucleotide sequence encoding the antibody or the antibody fragment; a transformed cell which contains a vector carrying the nucleic acid; a method for producing the antibody or the antibody fragment using the hybridoma or the transformed cell; a therapeutic agent and a diagnostic agent, each of which contains the antibody or the antibody fragment; and a method for treating a CCR1-related disease and a method for diagnosing a CCR1-related disease, in each of which the antibody or the antibody fragment is used.
Inventors:
KAI MASAYUKI (JP)
TAKETO MAKOTO (JP)
KAWADA KENJI (JP)
HIRAI HIDEYO (JP)
SAKAI YOSHIHARU (JP)
MAEKAWA TAIRA (JP)
TAKETO MAKOTO (JP)
KAWADA KENJI (JP)
HIRAI HIDEYO (JP)
SAKAI YOSHIHARU (JP)
MAEKAWA TAIRA (JP)
Application Number:
PCT/JP2017/001687
Publication Date:
July 27, 2017
Filing Date:
January 19, 2017
Export Citation:
Assignee:
KYOWA HAKKO KIRIN CO LTD (JP)
UNIV KYOTO (JP)
UNIV KYOTO (JP)
International Classes:
C07K16/28; A61K39/395; A61P29/00; A61P35/00; A61P37/06; C12N5/10; C12N5/12; C12N15/09; C12P21/08; G01N33/53
Domestic Patent References:
| WO2000044789A1 | 2000-08-03 | |||
| WO2000044790A1 | 2000-08-03 |
Other References:
HWANG J. ET AL.: "Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo", FEBS LETTERS, vol. 570, 2004, pages 47 - 51, XP004520945, DOI: doi:10.1016/j.febslet.2004.06.023
LEBRE M. C. ET AL.: "Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis", PLOS ONE, vol. 6, no. 7, 2011, pages 1 - 7, XP055220514, DOI: doi:10.1371/journal.pone.0021772
OBA Y. ET AL.: "MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells", EXPERIMENTAL HEMATOLOGY, vol. 33, 2005, pages 272 - 278, XP004761282, DOI: 10.1016/j.exphem.2004.11.015
YOSHIRO, ITATANI ET AL.: "CCL15-CCR1 axis ni yoru Daichogan Kanten'i Kijo to, CCR1 Sogaiyaku ni yoru Kanten'i Yokusei eno Kitai", JOURNAL OF JAPAN SURGICAL SOCIETY, vol. 114, no. 2, 2013, pages 387
LEBRE M. C. ET AL.: "Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis", PLOS ONE, vol. 6, no. 7, 2011, pages 1 - 7, XP055220514, DOI: doi:10.1371/journal.pone.0021772
OBA Y. ET AL.: "MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells", EXPERIMENTAL HEMATOLOGY, vol. 33, 2005, pages 272 - 278, XP004761282, DOI: 10.1016/j.exphem.2004.11.015
YOSHIRO, ITATANI ET AL.: "CCL15-CCR1 axis ni yoru Daichogan Kanten'i Kijo to, CCR1 Sogaiyaku ni yoru Kanten'i Yokusei eno Kitai", JOURNAL OF JAPAN SURGICAL SOCIETY, vol. 114, no. 2, 2013, pages 387
Attorney, Agent or Firm:
Eikoh Patent Firm, P.C. (JP)
Download PDF: